Business Description
Alkem Laboratories Ltd
ISIN : INE540L01014
Total Employee Number:
22,833Compare
Compare
Traded in other countries / regions
ALKEM.India IPO Date
2015-12-23Description
Alkem Laboratories Ltd is a diversified healthcare company engaged in the pharmaceutical business with operations. The Company is engaged in the development, manufacture, and sale of pharmaceutical products. It operates in one reportable business segment, Pharmaceuticals. Its operations include Domestic Pharma (Branded & Trade Generics, ActivLife and Alkem), Biotech (Biosimilars & Bio-CDMO), MedTech and Activa, and International Business. It focuses on chronic therapies, including anti-diabetes, dermatology, urology, and inhaled chronic respiratory. It caters to pharmaceutical firms, distributors, wholesalers, pharmacy chains, hospitals, and other healthcare-related institutional customers across domestic and international markets. It generates the maximum revenue from the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.99 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.15 | |||||
Debt-to-EBITDA | 0.59 | |||||
Interest Coverage | 14.85 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 8.32 | |||||
Beneish M-Score | -2.2 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.3 | |||||
3-Year EBITDA Growth Rate | 25.4 | |||||
3-Year EPS without NRI Growth Rate | 31.7 | |||||
3-Year FCF Growth Rate | -2.4 | |||||
3-Year Book Growth Rate | 15.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 8.15 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 8.99 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 23.31 | |||||
9-Day RSI | 33.66 | |||||
14-Day RSI | 39.47 | |||||
3-1 Month Momentum % | 0.35 | |||||
6-1 Month Momentum % | 3.64 | |||||
12-1 Month Momentum % | 4.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.55 | |||||
Quick Ratio | 1.86 | |||||
Cash Ratio | 0.85 | |||||
Days Inventory | 219.99 | |||||
Days Sales Outstanding | 68.87 | |||||
Days Payable | 144.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.98 | |||||
Dividend Payout Ratio | 0.27 | |||||
3-Year Dividend Growth Rate | 39 | |||||
Forward Dividend Yield % | 0.37 | |||||
5-Year Yield-on-Cost % | 1.84 | |||||
Shareholder Yield % | -0.23 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 66.03 | |||||
Operating Margin % | 17.49 | |||||
Net Margin % | 14.31 | |||||
EBITDA Margin % | 22.84 | |||||
FCF Margin % | 8.92 | |||||
OCF Margin % | 13.02 | |||||
ROE % | 16.53 | |||||
ROA % | 11 | |||||
ROIC % | 15.72 | |||||
3-Year ROIIC % | 38.06 | |||||
ROC (Joel Greenblatt) % | 42.91 | |||||
ROCE % | 20.23 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 29.75 | |||||
Forward PE Ratio | 28.65 | |||||
PE Ratio without NRI | 28.12 | |||||
Shiller PE Ratio | 38 | |||||
Price-to-Owner-Earnings | 31.73 | |||||
PEG Ratio | 2.7 | |||||
PS Ratio | 4.26 | |||||
PB Ratio | 4.64 | |||||
Price-to-Tangible-Book | 4.98 | |||||
Price-to-Free-Cash-Flow | 47.69 | |||||
Price-to-Operating-Cash-Flow | 32.7 | |||||
EV-to-EBIT | 20.56 | |||||
EV-to-EBITDA | 18.2 | |||||
EV-to-Forward-EBITDA | 18.42 | |||||
EV-to-Revenue | 4.16 | |||||
EV-to-Forward-Revenue | 3.71 | |||||
EV-to-FCF | 46.59 | |||||
Price-to-GF-Value | 0.87 | |||||
Price-to-Projected-FCF | 2.44 | |||||
Price-to-DCF (Earnings Based) | 1.79 | |||||
Price-to-DCF (FCF Based) | 4.27 | |||||
Price-to-Median-PS-Value | 1.08 | |||||
Price-to-Peter-Lynch-Fair-Value | 2.01 | |||||
Price-to-Graham-Number | 2.42 | |||||
| Price-to-Net-Current-Asset-Value | 12.44 | |||||
Earnings Yield (Greenblatt) % | 4.86 | |||||
FCF Yield % | 2.1 | |||||
Forward Rate of Return (Yacktman) % | 12.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alkem Laboratories Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 150,812.8 | ||
| EPS (TTM) (₹) | 180.44 | ||
| Beta | 0.8228 | ||
| 3-Year Sharpe Ratio | 0.34 | ||
| 3-Year Sortino Ratio | 0.66 | ||
| Volatility % | 10.64 | ||
| 14-Day RSI | 39.47 | ||
| 14-Day ATR (₹) | 141.266876 | ||
| 20-Day SMA (₹) | 5604.7725 | ||
| 12-1 Month Momentum % | 4.73 | ||
| 52-Week Range (₹) | 5085 - 5933 | ||
| Shares Outstanding (Mil) | 119.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alkem Laboratories Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alkem Laboratories Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2027 | 2027-02-12 16:00 | In 182 days | ||
| Third quarter earnings results for 2027 | 2027-02-12 | In 181 days | ||
| Second quarter earnings conference call for 2027 | 2026-11-13 16:30 | In 91 days | ||
| Second quarter earnings results for 2027 | 2026-11-13 | In 90 days | ||
| General meeting for 2026 | 2026-08-27 11:00 | In 13 days | ||
| First quarter earnings conference call for 2027 | 2026-08-14 16:30 | 5,418.75 (-0.94%) | ||
| First quarter earnings results for 2027 | 2026-08-14 | 5,418.75 (-0.94%) | ||
| INR 10.000000 Cash Dividend | 2026-08-07 | 5,608.45 (-0.76%) | ||
| Annual report for 2026 | 2026-07-29 | 5,650.40 (+0.90%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-28 16:30 | 5,452.25 (+1.34%) |
Show
Entries
Alkem Laboratories Ltd Frequently Asked Questions
What is Alkem Laboratories Ltd(BOM:539523)'s stock price today?
The current price of BOM:539523 is ₹5399.00. The 52 week high of BOM:539523 is ₹5933.00 and 52 week low is ₹5085.00.
When is next earnings date of Alkem Laboratories Ltd(BOM:539523)?
The next earnings date of Alkem Laboratories Ltd(BOM:539523) is 2026-11-13 Est..
Does Alkem Laboratories Ltd(BOM:539523) pay dividends? If so, how much?
The Dividend Yield %  of Alkem Laboratories Ltd(BOM:539523) is 0.98% (As of Today), Highest Dividend Payout Ratio of Alkem Laboratories Ltd(BOM:539523) was 0.31. The lowest was 0.08. And the median was 0.25. The  Forward Dividend Yield % of Alkem Laboratories Ltd(BOM:539523) is 0.37%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Alkem Laboratories Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers